Figure 6.1 (Savaysa 01)
Savaysa Tablet, Film Coated
Product Images NDC 65597-201
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Savaysa (NDC 65597-201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Daiichi Sankyo Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chemical Structure (Savaysa 02)
Figure 12.1 (Savaysa 03)
This text appears to be a list of drugs categorized as P-gp inhibitors or P-gp inducers. The P-gp inhibitors listed are Ketoconazole, Quinidine, Verapamil, Erythromycin, Cydosporine, Amiodarone, and Dronedarone. The P-gp inducer listed is Rifampin. Other drugs mentioned include Digoxin, Atorvastatin, Esomeprazole, Naproxen, Aspirin 325 mg, and Aspirin 100 mg. There is also a table displaying fold change and 90% confidence interval in PK and change relative to reference. However, the overall context or purpose of this text is not available.*
Figure 14.1 (Savaysa 04)
Figure 14.2 (Savaysa 05)
Figure 14.3 (Savaysa 06)
This appears to be a graph showing the estimated cumulative proportion of adjudicated recurrent VTE (venous thromboembolism) for SAVAYSA 60mg and Warfarin over a period of 360 days. The x-axis represents the time to recurrent VTE in days and the y-axis shows the estimated cumulative proportion. The graph has two lines, one for SAVAYSA and one for Warfarin, which intersect at various points on the graph. The number of patients at risk for SAVAYSA and Warfarin are also displayed at the bottom of the graph.*
15 mg 30-count Bottle Label (Savaysa 07)
Each tablet contains 15mg edoxaban, equivalent to 20.20mg of edoxaban tosylate monohydrate. This prescription medicine should be kept at a temperature between 20-25°C (68-77°F), with some excursions permitted at 15-30°C (59-86°F), and out of reach of children. The dosage and usage instructions can be found in the package insert, alongside a medication guide that should be given to each patient. Manufactured for Daichi Sankyo, Inc. with NDC 65597-201-30.*
30 mg 30-count Bottle Label (Savaysa 08)
This is a description of a medication called Savaysa. Each tablet contains 30mg of edoxaban which is equivalent to 40.41mg of edoxaban tosylate monohydrate. The dosage and usage instructions can be found in the package insert. The tablets should be stored at a temperature between 20°C-25°C (68°F-77°F) with excursions permitted to 15°C-30°C (59°F-86°F). The product is manufactured by Daiichi Saniyo, Inc. and is a product of Japan. The medication should be kept out of the reach of children. Each box of Savaysa contains 30 tablets and dispense a medication guide to each patient.*
30 mg 90-count Bottle Label (Savaysa 09)
This appears to be a description of a medication called edoxaban. Each tablet contains 30mg of edoxaban tosylate monotyate. It is recommended to store the medication at 20°C-25°C (68°F-77°F) and excursions are permitted to 15°C-30°C (59°F-86°F). It is manufactured by Daichi Sanyo in Japan. Dosage and usage should be referred to the package insert. The text also includes some symbols and characters that could not be identified as readable text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
